TABLE 5.
Sensitivity analyses results: rt‐CGM versus FGM
| Analysis | Cost, AUD | Quality‐adjusted life expectancy, QALYs | ICER, AUD per QALY gained | ||||
|---|---|---|---|---|---|---|---|
| rt‐CGM | FGM | Difference | rt‐CGM | FGM | Difference | ||
| Base case | 246,146 | 235,082 | +11,064 | 9.362 | 8.235 | +0.569 | 19,455 |
| rt‐CGM HbA1c –30% | 253,968 | 235,082 | +18,886 | 9.278 | 8.235 | +0.486 | 38,892 |
| rt‐CGM HbA1c +30% | 239,102 | 235,082 | +4,020 | 9.431 | 8.235 | +0.638 | 6,302 |
| rt‐CGM SHE rate –50% | 244,792 | 235,082 | +9,709 | 9.369 | 8.793 | +0.576 | 16,842 |
| rt‐CGM SHE rate +50% | 247,447 | 235,082 | +12,365 | 9.344 | 8.793 | +0.551 | 22,424 |
| rt‐CGM NSHE rate –50% | 246,146 | 235,082 | +11,064 | 9.533 | 8.793 | +0.741 | 14,939 |
| rt‐CGM NSHE rate +50% | 246,146 | 235,082 | +11,064 | 9.309 | 8.793 | +0.516 | 21,421 |
| No QoL difference in monitoring method | 246,146 | 235,082 | +11,064 | 9.065 | 8.793 | +0.273 | 40,587 |
| QoL difference of monitoring method reduced by 50% | 246,146 | 235,082 | +11,064 | 9.214 | 8.793 | +0.421 | 26,305 |
| QoL difference of monitoring method increased by 50% | 246,146 | 235,082 | +11,064 | 9.510 | 8.793 | +0.717 | 15,435 |
| Fingerstick test for FGM =3 times/day | 246,146 | 237,456 | +8,690 | 9.362 | 8.793 | +0.569 | 15,282 |
| Fingerstick test for FGM =4 times/day | 246,146 | 238,247 | +7,899 | 9.362 | 8.793 | +0.569 | 13,891 |
| Fingerstick test for FGM =5 times/day | 246,146 | 239,038 | +7,108 | 9.362 | 8.793 | +0.569 | 12,500 |
| Cost of FGM –20% | 246,146 | 230,739 | +15,407 | 9.362 | 8.235 | +0.569 | 27,077 |
| Cost of FGM +20% | 246,146 | 239,413 | +6,733 | 9.362 | 8.235 | +0.569 | 11,833 |
| Discount rate 3.5% | 318,245 | 307,456 | +10,789 | 11.384 | 10.666 | +0.718 | 15,024 |
| Discount rate 0% | 675,215 | 669,811 | +5,404 | 20.241 | 18.803 | +1.438 | 3757 |
Abbreviations: AUD, Australian dollar; ICER, incremental cost‐effectiveness ratio; NSHE, non‐severe hypoglycaemic event; QALY, quality‐adjusted life year; QoL, quality of life; rt‐CGM, real‐time continuous glucose monitoring; SHE, severe hypoglycaemic event; SMBG, self‐monitoring of blood glucose; T1D, type 1 diabetes.